CMS – Page 61 – medicarereport.org

Friday, September 11, 2026

Latest:

CMS Health Care Finance Medicare Advantage

Eileen Cook July 19, 2023July 19, 2023 CMS, Medicare Advantage, Medicare Advantage Overpayments, Medicare Advantage Risk Adjustment

3 ways to reduce Medicare Advantage overpayments

(By Rylee Wilson for Becker’s Hospital Review ) Medicare Advantage overpayments may be higher than the the Medicare Payment and

Alzheimer’s/Dementia CMS FDA Health Care Finance Medicare - General Part D/Prescription Drugs

Eileen Cook July 14, 2023July 14, 2023 Alzheimer’s Disease, CMS, Leqembi, medicare, Medicare Advantage, Medicare Part D, Older Adults

Will the new Alzheimer’s drug put pressure on Medicare premiums?

The FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the

CMS Health Care Finance Part D/Prescription Drugs

Eileen Cook July 13, 2023July 13, 2023 CMS, medicare, Medicare Part D, Prescription drug coverage, Prescription Drug Spending

10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year

(By Chris Lee for The Kaiser Family Foundation published July 12, 2023) A new KFF analysis finds that the 10

Affordable Care Act (ACA)CMS Health Care Finance Health Insurance

Eileen Cook July 12, 2023July 12, 2023 ACA, CMS, Health Insurance, Risk Adjustment Payments, Small Groups

ACA risk adjustment payments are on the rise: CMS

(By Rylee Wilson for Becker’s Hospital Review ) Total risk adjustment payments in individual and small group insurance plans increased

Aging Alzheimer’s/Dementia CMS FDA Health Care Finance Part D/Prescription Drugs

Eileen Cook July 11, 2023July 11, 2023 Alzheimer’s Disease, CMS, Healthcare Costs, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Leqembi could cost Medicare up to $17.8B

(By Rylee Wilson for Becker’s Hospital Review ) Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease,

Alzheimer’s/Dementia CMS FDA Part D/Prescription Drugs

Eileen Cook July 10, 2023July 10, 2023 Alzheimer’s Disease, CMS, FDA, Lecanemab Drug, Medicare Part D

Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval

(Source - www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following

Affordable Care Act (ACA)CMS Medicare Advantage

Eileen Cook July 7, 2023July 7, 2023 ACA, CMS, High-quality Care, Medicare Advantage, Medicare Advantage Star Ratings

Medicare Advantage star ratings are failing to improve plan quality: Study

(By Jakob Emerson for Becker’s Hospital Review ) The Medicare Advantage star rating system and its quality bonus payment program

CMS Medicare - General Part D/Prescription Drugs

Eileen Cook July 6, 2023July 6, 2023 CMS, medicare, Medicare Drug Price Negotiation Program, Medicare Part D, Revised Guidance

CMS Releases Revised Guidance for Historic Medicare Drug Price Negotiation Program

(Source - www.cms.gov/newsroom) For the first time in history, Medicare has the ability to directly negotiate the prices of covered

CMS Health Care Redesign Medicare Advantage

Eileen Cook June 28, 2023June 28, 2023 2-Midnight Rule, CMS, Inpatient Hospital, Medicare Advantage, Outpatient Hospital

The 2-midnight rule and Medicare Advantage: 6 things to know

(By Jakob Emerson for Becker’s Hospital Review ) There are major changes afoot for Medicare Advantage plans and when they

Alzheimer’s/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

Eileen Cook June 26, 2023June 26, 2023 Aducanumab, Alzheimer’s Disease, CMS, FDA, Lecanemab Drug, medicare, Older Adults

An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why

(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval